Arbutus Biopharma Corp (ABUS-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	N/A	N/A	$-0.16	N/A
Number of Estimates	0	0	1	0
High Estimate	N/A	N/A	$-0.16	N/A
Low Estimate	N/A	N/A	$-0.16	N/A
Prior Year	$-0.13	$0.01	$-0.17	$-0.16
Growth Rate Est. (year over year)	+768,561.54%	+9,989,900.00%	+5.88%	+624,475.00%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$-0.01	$-0.04	$0.01	$-0.13
Estimate	N/A	N/A	$-0.02	$-0.09
Difference	N/A	N/A	+0.03	-0.04
Surprise	N/A	N/A	+150.00%	-44.44%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.50

3 Mths Ago4

4.33

2 Mths Ago3

4.33

1 Mth Ago3

4.33

Current3

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	4	3	3	3
	3	2	2	2
Holds	1	1	1	1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Lululemon appoints long-time Nike executive Heidi O’Neill as new CEO

Bullish on Pembina Pipeline Corp.

How investors should digest the stock market’s ‘sugar high’

Market Factors: Top picks, sector review for income-heavy utilities sector

The most oversold and overbought stocks on the TSX

The highest-yielding stocks on the TSX, plus risk data

Barlow’s Research Roundup: These stocks are biggest winners from oil price volatility

It’s not just Allbirds - another meme-stock season is on the horizon, Vanda Research says